Literature DB >> 18096230

The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Fredrik Bexborn1, Per Ola Andersson, Hui Chen, Bo Nilsson, Kristina N Ekdahl.   

Abstract

The molecular interactions between the components of the C3 convertase of the alternative pathway (AP) of complement and its regulators, in both surface-bound and fluid-phase form, are still incompletely understood. The fact that the AP convertase is labile makes studies difficult to perform. According to the so called tick-over theory, hydrolyzed C3, called C3(H(2)O), forms the initial convertase in fluid phase together with factor B. In the present study, we have applied western blot analysis and ELISA together with fluorescence resonance energy transfer (FRET) to study the formation of the fluid-phase AP convertases C3(H(2)O)Bb and C3bBb and their regulation by factor H and factor I at specific time points and, with FRET, in real time. In our hands, factor B showed a higher affinity for C3(H(2)O) than for C3b, although in both cases it was readily activated to Bb. However, the convertase activity of C3bBb was approximately twice that of C3(H(2)O)Bb, as monitored by the generation of C3a. But in contrast, the C3(H(2)O)Bb convertase was more resistant to inactivation by factor H and factor I than was the C3bBb convertase. Under conditions that totally inactivated C3bBb, C3(H(2)O)Bb still retained approximately 25% of its initial activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096230      PMCID: PMC2701500          DOI: 10.1016/j.molimm.2007.11.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  40 in total

1.  Purification of human complement factor D from the peritoneal fluid of patients on chronic ambulatory peritoneal dialysis.

Authors:  E Catana; J A Schifferli
Journal:  J Immunol Methods       Date:  1991-04-25       Impact factor: 2.303

2.  Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.

Authors:  A Ueda; J F Kearney; K H Roux; J E Volanakis
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

3.  A thermodynamic study of the interaction between human complement components C3b or C3(H2O) and factor B in solution.

Authors:  E L Pryzdial; D E Isenman
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

4.  Reinvestigations into the formation and assay of C3bBbP complexes.

Authors:  S S Asghar; C Y Barendsen; H J van der Helm
Journal:  Clin Chim Acta       Date:  1987-06-15       Impact factor: 3.786

5.  Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

6.  A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement.

Authors:  M K Pangburn
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

7.  Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.

Authors:  J D Lambris; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1984-10-25       Impact factor: 5.157

8.  Generation of iC3 at the interface between blood and gas.

Authors:  K Nilsson Ekdahl; B Nilsson; M Pekna; U R Nilsson
Journal:  Scand J Immunol       Date:  1992-01       Impact factor: 3.487

9.  A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3.

Authors:  B Nilsson; K E Svensson; M Inganäs; U R Nilsson
Journal:  J Immunol Methods       Date:  1988-03-16       Impact factor: 2.303

10.  Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.

Authors:  E L Pryzdial; D E Isenman
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

View more
  63 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus).

Authors:  Isabell C Pechtl; Robert K Neely; David T F Dryden; Anita C Jones; Paul N Barlow
Journal:  Protein Sci       Date:  2011-12       Impact factor: 6.725

Review 3.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

Review 4.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

5.  Properdin binding to complement activating surfaces depends on initial C3b deposition.

Authors:  Morten Harboe; Christina Johnson; Stig Nymo; Karin Ekholt; Camilla Schjalm; Julie K Lindstad; Anne Pharo; Bernt Christian Hellerud; Kristina Nilsson Ekdahl; Tom Eirik Mollnes; Per H Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

6.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Authors:  Geoffrey Gifford; Vivian P Vu; Nirmal K Banda; V Michael Holers; Guankui Wang; Ernest V Groman; Donald Backos; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2019-04-08       Impact factor: 9.776

7.  A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.

Authors:  Rasmus K Jensen; Rasmus Pihl; Trine A F Gadeberg; Jan K Jensen; Kasper R Andersen; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2018-03-01       Impact factor: 5.157

Review 8.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

Review 9.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

Review 10.  The role of the complement system in metabolic organs and metabolic diseases.

Authors:  Julia Phieler; Ruben Garcia-Martin; John D Lambris; Triantafyllos Chavakis
Journal:  Semin Immunol       Date:  2013-05-17       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.